The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial
Open accessAbstract
Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Naghavi, M., Abajobir, A. A., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abera, S. F., Aboyans, V., Adetokunboh, O., Afshin, A., Agrawal, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32152-9 · Cited by 4,821
Self-citationZhou, M., Wang, H., Zhu, J., Chen, W., Wang, L., Liu, S., Li, Y., Wang, L., Liu, Y., Yin, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00551-6 · Cited by 1,464
Self-citationChamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00114-9 · Cited by 1,198
Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30115-1 · Cited by 935
NXY-059 for the Treatment of Acute Ischemic Stroke
Shuaib, A., Lees, K. R., Lyden, P., Grotta, J., Davalos, A., Davis, S. M., Diener, H.-C., Ashwood, T., Wasiewski, W. W., & Emeribe, U. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070240 · Cited by 732
NXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660
Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction
(2003) · Cerebrovascular Diseases · doi:10.1159/000069318 · Cited by 660
Hill, M. D., Goyal, M., Menon, B. K., Nogueira, R. G., McTaggart, R. A., Demchuk, A. M., Poppe, A. Y., Buck, B. H., Field, T. S., Dowlatshahi, D., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30258-0 · Cited by 647
Self-citation
Cited by
Bioactive Ceria Nanoenzymes Target Mitochondria in Reperfusion Injury to Treat Ischemic Stroke
Liao, J., Li, Y., Fan, L., Sun, Y., Gu, Z., Xu, Q.-Q., Wang, Y., Xiong, L., Xiao, K., Chen, Z.-S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10982 · Cited by 104
Self-citationThe Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke
Wicks, E. E., Ran, K. R., Kim, J. E., Xu, R., Lee, R. P., & Jackson, C. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897022 · Cited by 92
Metadata
- Authors
- Xu, J., Wang, A., Meng, X., Yalkun, G., Xu, A., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., Zhu, R., Liu, B., Dong, A., Mu, H., Lu, Z., Li, S., Zheng, H., Chen, X., Wang, Y., Zhao, X., Wang, Y., Wang, Y., Xu, A., Zhao, X., Chen, X., Wang, Y., Meng, X., Wang, Y., Xu, J., Wang, A., Zheng, H., Gao, Z., Duan, L., Zhang, J., Li, S., Lou, D., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., Zhu, R., Liu, B., Dong, A., Liang, Q., Yang, H., Guo, C., Li, X., He, M., Tian, X., Cui, Y., Zhou, J., Wang, N., Wang, L., Zhang, X., Gao, X., Lu, L., Li, T., Cheng, Y., Liu, K., Xi, X., Wang, B., Sun, L., Zhao, S., Chu, X., Lian, Y., Yan, F., Wang, X., Wang, D., Shao, B., Jiao, J., Wu, H., Li, G., Guo, L., Wang, Y., Pan, S., Xu, A., Li, H., Zhuang, J., Li, X., Wu, J., Wang, A., Lou, D., Zuo, Y., Zhang, Y., Zhang, X., Feng, X., Meng, X., Wang, D., Dong, K., Liu, Y., Li, H., Chen, D., & Lv, Q.
- Venue
- Stroke
- Published
- 2021-03
- Volume
- 52
- Issue
- 3
- Pages
- 772-780
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W3129319285
- Cited by
- 261
- References
- 30
- FWCI
- 19.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. https://app.cochat.ai/papers/10.1161/strokeaha.120.031197
- The paper
- Xu, J., Wang, A., Meng, X., Yalkun, G., Xu, A., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., Zhu, R., Liu, B., Dong, A., Mu, H., Lu, Z., Li, S., Zheng, H., Chen, X., Wang, Y., . . . Lv, Q. (2021). Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. https://doi.org/10.1161/strokeaha.120.031197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.